PET imaging of solid tumors with 89Zr-DFO-starPEG
Part of Cancer clinical trials.
This early-phase trial tests a new imaging agent called 89Zr-DFO-starPEG that may help doctors see solid tumors more clearly on PET scans. It is a safety and imaging study, not a treatment, and may help find tumors in people with various types of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a solid tumor cancer that has been confirmed by a biopsy or lab test.
- You must have at least one tumor that is 1 cm or larger on a CT, MRI, or PET scan, or a spot on your bones that shows up on a PET scan.
- You must be able to have a PET/CT scan and have good liver and kidney function (based on blood tests in the last 4 weeks).
- If you are able to become pregnant, you must agree to use two forms of birth control or abstain from sex for 1 month after the study drug is given.
- You cannot be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging agent, [89Zr]DFO-YS5, to see if it can help detect and map certain cancers (including malignant peripheral nerve sheath tumors, bladder cancer, and other solid tumors) during PET scans. It may help doctors see cancerous lesions more clearly.
This study uses a special PET scan to see if a new imaging agent can help find and monitor certain solid tumors. It is for people with colon, rectal, sarcoma, breast, lung, head and neck, esophageal, stomach, pancreas, bladder cancers, or glioblastoma who have had standard treatment before surgery.
This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.
This trial tests a special imaging agent (a nanobody probe) that targets a protein called CD147 on tumor cells. If you have a solid tumor like melanoma, liver, colorectal, pancreatic, breast, stomach, or lung cancer, the PET scan may help doctors see your cancer more clearly.
This trial tests a new imaging agent that targets a protein called CD147, which is found on many solid tumors. The goal is to see if this agent can help doctors better stage your cancer using a PET/CT scan.
This trial is testing a new imaging agent called RT01-89Zr to see if it can help detect solid tumors during PET/CT scans. It involves an injection of the agent followed by imaging, and may offer a more targeted way to visualize tumors.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.